Výsledky vyhledávání - "Laurence T, Rimsky"

Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE

Autor: Johan Vingerhoets, Sandra De Meyer, Kim Thys, Veerle Van Eygen, Carl Van Hove, Gaston Picchio, Laurence T. Rimsky, Jeroen Aerssens

Publikováno v: Journal of Medical Virology. 88:798-806

Minority variants (1.0-25.0%) were evaluated by deep sequencing (DS) at baseline and virological failure (VF) in a selection of antiretroviral treatment-naive, HIV-1-infected patients from the rilpivirine ECHO/THRIVE phase III studies. Linkage betwee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c4e24a869e7c3c92553a4c4504f591e4
https://doi.org/10.1002/jmv.24395

Zobrazit plný text záznamu

Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV-1-Infected Patients with HIV-1 RNA <= 100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis

Autor: Georg Behrens, Jennifer Demorin, Simon Vanveggel, Susan K. Chuck, Calvin J. Cohen, Bart J. A. Rijnders, Marita Stevens, Richard Elion, David Thorpe, Laurence T. Rimsky, Chloe Orkin, Mark T. Nelson, Anthony Mills, Matthew Bosse, Lijie Zhong, Kirsten L. White

Publikováno v: AIDS Patient Care and STDs, 28(4), 168-175. Mary Ann Liebert Inc.

The once daily, single-tablet regimen (STR) combining rilpivirine (RPV), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) provides a simplified treatment option for antiretroviral therapy (ART)-naive patients with baseline HIV-1 RNA (BLVL

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::911adb8c4a3803b4d4deb62109946f12
https://hdl.handle.net/1765/57280

Zobrazit plný text záznamu

Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials

Autor: Echo, Simon Vanveggel, Chloe Orkin, J.-M. Molina, Marita Stevens, Laurence T. Rimsky, Nathan Clumeck, Thrive study groups

Publikováno v: HIV Medicine. 15:57-62

Objectives These 96-week, ECHO/THRIVE pooled analyses evaluated data for antiretroviral treatment-naive, HIV-1-infected adults with viral load (VL) ≤ 100 000 HIV-1 RNA copies/mL receiving rilpivirine or efavirenz. Methods ECHO and THRIVE were phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eac59ef7cfc4d92f0ab077d80734955d
https://doi.org/10.1111/hiv.12071

Zobrazit plný text záznamu

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less

Autor: Karla Redant, Simon Vanveggel, Laurence T. Rimsky, Marita Stevens, Jean-Michel Molina, Nathan Clumeck

Publikováno v: AIDS. 27:889-897

OBJECTIVES To compare efficacy, resistance development, and safety between rilpivirine and efavirenz in treatment-naive, HIV-1-infected adults with baseline viral load 100,000 copies/ml or less in the pooled 48-week dataset of the ECHO (Efficacy Comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::589854731330da21efaff5ee3021352b
https://doi.org/10.1097/qad.0b013e32835e1554

Zobrazit plný text záznamu

Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response

Autor: Katia Boven, Simon Vanveggel, Gaston Picchio, Steven Nijs, Johan Vingerhoets, Laurence T. Rimsky, Veerle Van Eygen

Publikováno v: Antiviral Therapy. 18:253-256

Background Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe797e5636562001dd5681f0e93bd61
https://doi.org/10.3851/imp2358

Zobrazit plný text záznamu

Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial

Autor: Aimee, Wilkin, Anton L, Pozniak, Javier, Morales-Ramirez, Sergio H, Lupo, Mario, Santoscoy, Beatriz, Grinsztejn, Kiat, Ruxrungtham, Laurence T, Rimsky, Simon, Vanveggel, Katia, Boven, Melanie, Thompson

Publikováno v: AIDS Research and Human Retroviruses. 28:437-446

TMC278-C204 (NCT00110305), a 96-week trial of the nonnucleoside reverse transcription inhibitor (NNRTI) rilpivirine (RPV, TMC278) in 368 HIV-1-infected, treatment-naive patients, was extended to investigate long-term safety and efficacy. Week 192 ana

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f975ea759a796a04072eff99c8d348
https://doi.org/10.1089/aid.2011.0050

Zobrazit plný text záznamu

The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness

Autor: Kerim Babaoglu, Eric B. Lansdon, Evguenia S. Svarovskaia, Laurence T. Rimsky, Veerle Van Eygen, Gaston Picchio, Michael D. Miller, Kirsten L. White, Rima Kulkarni

Publikováno v: JAIDS Journal of Acquired Immune Deficiency Syndromes. 59:47-54

Background The registrational phase III clinical trials of the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) in combination with two nucleoside/nucleotide RT inhibitors (NRTIs) found a unique genotypic resistance patter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1678a33b8dd0392aa46063257165be2
https://doi.org/10.1097/qai.0b013e31823aca74

Zobrazit plný text záznamu

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Autor: Khuanchai Supparatpinyo, Herta Crauwels, Jean-Michel Molina, Simon Vanveggel, Anthony Mills, Laurence T. Rimsky, Adriano Lazzarin, Michael S. Saag, Sharon Walmsley, Pedro Cahn, Katia Boven, Beatriz Grinsztejn

Publikováno v: The Lancet. 378:238-246

Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown sim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc13bd78fe7a3bac16d4e8d194eaf9c8
https://doi.org/10.1016/s0140-6736(11)60936-7

Zobrazit plný text záznamu

Short Communication: Activity of Etravirine on Different HIV Type 1 Subtypes:In VitroSusceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data

Autor: Steven Nijs, Johan Vingerhoets, Goedele De Smedt, Sandra De Meyer, Inge Dierynck, Hilde Azijn, Laurence T. Rimsky, Gaston Picchio, Marie-Pierre de Béthune, Lotke Tambuyzer

Publikováno v: AIDS Research and Human Retroviruses. 26:621-624

Etravirine (ETR) has previously shown potent in vitro activity against different primary HIV-1 isolates and demonstrated durable efficacy in treatment-experienced, HIV-1-infected patients in the Phase III DUET studies. The antiviral activity and effi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b236c0c03d66dbab097936be381015a
https://doi.org/10.1089/aid.2009.0239

Zobrazit plný text záznamu

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

Autor: Anton L, Pozniak, Javier, Morales-Ramirez, Elly, Katabira, Dewald, Steyn, Sergio H, Lupo, Mario, Santoscoy, Beatriz, Grinsztejn, Kiat, Ruxrungtham, Laurence T, Rimsky, Simon, Vanveggel, Katia, Boven, Aimee, Wilkin

Publikováno v: AIDS. 24:55-65

OBJECTIVE TMC278 is a next-generation nonnucleoside reverse transcriptase inhibitor highly active against wild-type and nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in vitro. The week 96 analysis of TMC278-C204, a large dose-ranging

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2989a64522eb89ac292a997dcefbd39
https://doi.org/10.1097/qad.0b013e32833032ed

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání